The technology, which includes the production of organ-like tissues called organoids under laboratory conditions, is one of the most important technologies in the field of health all over the world in the last 10 years.
Company co-founder Prof. Dr. Erdal and her team developed a method of obtaining 3D functional liver organoids from human pluripotent stem cells and used it in the modeling of Citrullinemia, an urea cycle disorder (Akbari S., et al. 2019). The company has exclusive licencing and commercialization rigths of eHEPO technology.
Patient-derived cancer organoid (PDCO) can be acquired from tumor resection/biopsies obtained from cancer patients . In the context of precision cancer therapy, it is possible to evaluate and predict drug responses utilizing PDCOs.
ORGANO-ID carries out TUBITAK Project under the National SME R&D Support Programme to develop a PDCO based chemotherapy response prediction Test Platform for Colorectal Carcinoma (CRC) and has already started to make biobank of patient derived CRC organoids. ORGANO-ID aims to adapt these technologies to different cancer models and then to offer the ORGANO-ID Test platform to patient service to determine the effectiveness of personalized drugs using these biobanks.